logo-loader

Kazia Therapeutics moves into operational phase of pivotal study for paxalisib in glioblastoma

Published: 14:23 21 Oct 2020 AEDT

Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott soon after announcing they've executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to begin participation in the GBM AGILE pivotal study in glioblastoma. The study is set to open a new arm with Kazia’s investigational new drug, paxalisib, and will now move into an operational phase with recruitment of patients to the paxalisib arm expected to begin in the first quarter of 2021.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

2 hours, 4 minutes ago